Uridine triacetate

Uridine triacetate, formerly known as vistonuridine, is an orally active tri-acetylated prodrug of uridine used:

in the treatment of hereditary orotic aciduria ;
to treat people following an overdose of chemotherapy drugs 5-fluorouracil or capecitabine regardless of the presence of symptoms, or who exhibit early-onset, severe or life-threatening toxicity affecting the cardiac or central nervous system, and/or early-onset, unusually severe adverse reactions within 96 hours following the end of fluorouracil or capecitabine administration.